Background
Study objectives
Methods
Study design
Patient population
ICM devices
Outpatient care
Statistical analysis
Ethical standards
Results
Study population
Characteristics | Patients with implant n = 88 | Patients without implant n = 14 | P-value |
---|---|---|---|
Age (years), median (range) | 66.5 (30–89) | 68.5 (47–82) | 0.556 |
Gender, n (%) | 0.214 | ||
Male | 54 (61.4) | 11 (78.6) | |
Female | 34 (38.6) | 3 (21.4) | |
Event, n (%) | 0.240 | ||
Stroke | 80 (90.9) | 14 (100) | |
Transient ischemic attack | 8 (9.1) | 0 | |
Body mass index (kg/m2), median (range) | 27 (19–49) | 28 (20–34) | 0.995 |
Comorbidity, n (%) | |||
Hypertension | 59 (67.0) | 10 (71.4) | 0.745 |
Diabetes mellitus | 20 (22.7) | 2 (14.3) | 0.476 |
Vasculopathy | 19 (21.6) | 1 (7.1) | 0.206 |
Heart failure | 3 (3.4) | 0 | 0.483 |
CHA2DS2-VASc score, median (range) | 4 (2–7) | 4.5 (2–7) | 0.870 |
Score 2, n (%) | 7 (8.0) | 2 (14.3) | |
Score 3, n (%) | 20 (22.7) | 3 (21.4) | |
Score 4, n (%) | 19 (21.6) | 2 (14.3) | |
Score 5, n (%) | 22 (25.0) | 2 (14.3) | |
Score 6, n (%) | 11 (12.5) | 3 (21.4) | |
Score 7, n (%) | 9 (10.2) | 2 (14.3) | |
Extrasystole, n (%) | 64 (72.7) | 0 | |
Number of drugs, median (range) | 4 (1–14) | 5 (2–10) | 0.709 |
Smocking status, n (%) | 0.069 | ||
Nonsmoker | 49 (55.7) | 8 (57.1) | |
Smoker | 25 (28.4) | 1 (7.1) | |
Ex-smoker | 12 (13.6) | 3 (21.4) | |
No indication | 2 (2.3) | 2 (14.3) |
Parameter | Overall population (n = 88) |
---|---|
Implant manufacturer, n (%) | |
Biotronik | 58 (65.9) |
Medtronic | 17 (19.3) |
St. Jude | 13 (14.8) |
Implant designation, n (%) | |
Biomonitor2-AF | 58 (65.9) |
Reveal LINQ | 2 (2.3) |
Reveal XT | 15 (17.0) |
SJM confirm | 13 (14.8) |
Tele-monitoring, n (%) | |
On | 58 (65.9) |
Off | 30 (34.1) |
Ambulatory follow-up care, n (%) | |
Rostock University Medical Center | 58 (65.9) |
Doctor’s office | 30 (34.1) |
Observation period (months), median (range) | 21.5 (1–33) |
AF events
Parameter | No atrial fibrillation n = 69 | Atrial fibrillation n = 19 | P-value |
---|---|---|---|
Age (years), median (range) | 64 (30–89) | 74 (47–83) | 0.060 |
Gender, n (%) | 0.377 | ||
Male | 44 (63.8) | 10 (52.6) | |
Female | 25 (36.2) | 9 (47.4) | |
Event, n (%) | 0.512 | ||
Stroke | 62 (89.9) | 18 (94.7) | |
Transient ischemic attack | 7 (10.1) | 1 (5.3) | |
Body mass index (kg/m2), median (range) | 27 (19–49) | 28 (23–44) | 0.478 |
Comorbidity, n (%) | |||
Hypertension | 47 (68.1) | 12 (63.2) | 0.684 |
Diabetes mellitus | 17 (24.6) | 3 (15.8) | 0.415 |
Vasculopathy | 16 (23.2) | 3 (15.8) | 0.488 |
Heart failure | 3 (4.3) | 0 | 0.355 |
CHA2DS2-VASc score, median (range) | 4 (2–7) | 5 (2–7) | 0.346 |
Score 2, n (%) | 6 (8.7) | 1 (5.3) | |
Score 3, n (%) | 16 (23.2) | 4 (21.1) | |
Score 4, n (%) | 16 (23.2) | 3 (15.8) | |
Score 5, n (%) | 17 (24.6) | 5 (26.3) | |
Score 6, n (%) | 7 (10.1) | 4 (21.1) | |
Score 7, n (%) | 7 (10.1) | 2 (10.5) | |
Extrasystole, n (%) | 52 (75.4) | 12 (63.2) | 0.290 |
Number of drugs, median (range) | 4 (1–14) | 5 (2–8) | 0.992 |
Smocking status, n (%) | 0.720 | ||
Nonsmoker | 37 (53.6) | 12 (63.2) | |
Smoker | 21 (30.4) | 4 (21.1) | |
Ex-smoker | 9 (13.0) | 3 (15.8) | |
No indication | 2 (2.9) | 0 | |
Observation period (months), median (range) | 23 (1–33) | 7 (1–32) | 0.002 |
Recurrent stroke during observation period, n (%) | XX | XX | XX |